NCT00354250View on ClinicalTrials.gov

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2007

Conditions
Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

ispinesib

Given IV

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00354250 - Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer | Biotech Hunter | Biotech Hunter